1. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Issue 15 (November 2015) Authors: Tournigand, Christophe; Chibaudel, Benoist; Samson, Benoit; Scheithauer, Werner; Vernerey, Dewi; Mésange, Paul; Lledo, Gérard; Viret, Frédéric; Ramée, Jean-François; Tubiana-Mathieu, Nicole; Dauba, Jérôme; Dupuis, Olivier; Rinaldi, Yves; Mabro, May; Aucoin, Nathalie; Latreille, Jean; Bonnetain, F... Journal: Lancet oncology Issue: Volume 16:Issue 15(2015) Page Start: 1493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. (September 2019) Authors: Scheithauer, Werner; Putora, Paul Martin; Grünberger, Birgit; Eisterer, Wolfgang; Wöll, Ewald; Prager, Gerald; Schaberl-Moser, Renate; Greil, Richard; Glatzer, Markus Journal: Therapeutic advances in gastroenterology Issue: Volume 12(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. (January 2019) Authors: Gargiulo, Piera; Dietrich, Daniel; Herrmann, Richard; Bodoky, György; Ruhstaller, Thomas; Scheithauer, Werner; Glimelius, Bengt; Berardi, Simona; Pignata, Sandro; Brauchli, Peter Journal: Therapeutic advances in medical oncology Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. (July 2019) Authors: Kieler, Markus; Unseld, Matthias; Bianconi, Daniela; Scheithauer, Werner; Prager, Gerald W. Journal: Therapeutic advances in medical oncology Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. (August 2020) Authors: Bianconi, Daniela; Herac, Merima; Posch, Florian; Schmeidl, Margit; Unseld, Matthias; Kieler, Markus; Brettner, Robert; Müllauer, Leonhard; Riedl, Jakob; Gerger, Armin; Scheithauer, Werner; Prager, Gerald Journal: Therapeutic advances in medical oncology Issue: Volume 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. Issue 187 (March 2020) Authors: Moik, Florian; Posch, Florian; Grilz, Ella; Scheithauer, Werner; Pabinger, Ingrid; Prager, Gerald; Ay, Cihan Journal: Thrombosis research Issue: Issue 187(2020) Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Mode of action of maintenance immunotherapy therapy with the TLR-9 agonist MGN1703 in metastatic colorectal carcinoma: the Phase III IMPALA study. (4th November 2015) Authors: Stein, Alexander; Kapp, Kerstin; Scheithauer, Werner; Salazar, Ramon; Ducreux, Michel; Waddell, Tom; Arnold, Dirk; Tournigand, Christophe; Sobrero, Alberto; Van Cutsem, Eric; Schmidt, Manuel; Cunningham, David Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. (12th January 2015) Authors: Tabernero, Josep; Chiorean, E. Gabriela; Infante, Jeffrey R.; Hingorani, Sunil R.; Ganju, Vinod; Weekes, Colin; Scheithauer, Werner; Ramanathan, Ramesh K.; Goldstein, David; Penenberg, Darryl N.; Romano, Alfredo; Ferrara, Stefano; Von Hoff, Daniel D. Journal: Oncologist Issue: Volume 20:Number 2(2015) Page Start: 143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Issue 23 (28th September 2015) Authors: Pavo, Noemi; Raderer, Markus; Hülsmann, Martin; Neuhold, Stephanie; Adlbrecht, Christopher; Strunk, Guido; Goliasch, Georg; Gisslinger, Heinz; Steger, Günther G; Hejna, Michael; Köstler, Wolfgang; Zöchbauer-Müller, Sabine; Marosi, Christine; Kornek, Gabriela; Auerbach, Leo; Schneider, Sven; Parsc... Journal: Heart Issue: Volume 101:Issue 23(2015) Page Start: 1874 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Mode of action of maintenance immunotherapy therapy with the TLR-9 agonist MGN1703 in metastatic colorectal carcinoma: the Phase III IMPALA study. Issue 2 (December 2015) Authors: Stein, Alexander; Kapp, Kerstin; Scheithauer, Werner; Salazar, Ramon; Ducreux, Michel; Waddell, Tom; Arnold, Dirk; Tournigand, Christophe; Sobrero, Alberto; Van Cutsem, Eric; Schmidt, Manuel; Cunningham, David Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗